SLC5A2 and Hyperkalemia: Mechanistically, the effects of SGLT-2 inhibition on intraglomerular pressure appear to complement the effects of RAS inhibition (Figure 1) without causing hyperkalaemia or acute kidney injury, so their combination may have the potential to benefit those at risk of hyperfiltration (i.e., those with reduced eGFR and/or albuminuria).